The long-term success of national efforts to reduce breast cancer incidence and mortality rests in part on the ability of Breast Cancer SPORE programs to attract and build the translational research careers of talented young faculty. Since 1992, the UNC Breast Cancer SPORE has used career development funds to promote the breast cancer research careers of selected investigators. The SPORE Career Enhancement Program (CEP) both recruits externally and identifies internal faculty with interest in translational breast cancer research. The CEP then matches junior faculty with training offerings and senior mentors. We seek to enrich the field with our efforts to recruit qualified women and minorities as both participants and mentors in the program. Over the 24 years of the program recruits funded by the CEP include 17 women and six minority faculty (three African Americans, three Hispanic). Co-recruitment with departments across campus attracts exceptional talent to UNC and its Cancer Center. The SPORE CEP makes available extended training for junior faculty with an interactive group of respected and successful investigators who can influence and help build careers. The combination of an excellent talent pool and an effective training and mentoring program has resulted in an elite cadre of breast cancer researchers whose work contributes to the national breast cancer effort. Over the last six years the CEP has attracted 13 participants; five were women and three were minorities. We are particularly pleased that six of the 13 recruits were named Komen Career Catalyst Scholars (as was one DRP Awardee) and several have already been funded by NCI. These CEP participants? contributions include published research, funded grants and collaborative breast cancer research across the spectrum of population, basic, clinical and translational research. Over the course of the CEP program a number of participants have become SPORE leaders. These include Bob Millikan, who developed CBCS; Charles Perou, Multi-PI and co- leader of Project 3; Lisa Carey Co-program head and co-leader of Projects 1 and 3 and the Career Enhancement Program; Melissa Troester, co-leader of Project 1; Carey Anders, clinical trial leader of Project #4; Claire Dees co-investigator on Project #2 and Katie Hoadley co-investigator Project #1, #3 and the Bioinformatics / Biostatistics Core. Over the next five years, the UNC Breast Cancer SPORE will continue to promote and develop careers in translational breast cancer research. The UNC Breast Cancer SPORE requests $50,000 to support career development. These funds will combine with $400-600,000 yearly in institutional funds to provide for recruitment and career development of faculty in translational breast cancer research. The SPORE leaders will continue to identify, recruit, and develop minority and women faculty.

Public Health Relevance

Career Development Program Project Narrative The Career Development Program of the UNC Breast SPORE prepares the next generation of translational breast cancer researchers. A successful Program of training, recruitment, and mentoring has brought 13 participants to the UNC Breast Cancer SPORE over the last cycle; five were women and three were minorities. Their success is noted by publications, new grants, with six of them being awarded Komen Career Catalyst Awards.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-26
Application #
10011772
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1997-08-05
Project End
2023-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
26
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Butler, Eboneé N; Bensen, Jeannette T; Chen, Mengjie et al. (2018) Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors. Cancer Epidemiol Biomarkers Prev 27:67-74
Echavarria, Isabel; López-Tarruella, Sara; Picornell, Antoni et al. (2018) Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res 24:1845-1852
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381

Showing the most recent 10 out of 598 publications